Apeiron Partners

id4 A.G., founded in 2019 and headquartered in Lucerne, Switzerland, specializes in developing a comprehensive Client Lifecycle Management digital platform. This platform is designed to assist businesses in navigating and adhering to increasingly stringent regulatory requirements. As a subsidiary of Apeiron Holdings A.G., id4 focuses on delivering solutions that streamline compliance processes for its clients in the regulatory technology sector.

EnBiotix, Inc. is a biotechnology company focused on developing and commercializing innovative products for chronic and recurrent pulmonary infections, as well as other diseases. The company employs advanced synthetic biology and systems biology platforms to enhance the efficacy of existing antibiotics and address the growing challenge of drug-resistant bacterial infections. EnBiotix's product pipeline includes promising candidates such as EBX-001 for Pseudomonas aeruginosa infections in cystic fibrosis patients, EBX-002 for catheter-associated urinary tract infections, and EPP-001 for prosthetic joint infections. Founded in 2010 and based in Boston, Massachusetts, EnBiotix aims to significantly improve treatment options for patients facing life-threatening infections in a market that exceeds $40 billion.